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Abstract
CTGF is a secreted matricellular protein with very complex biology. It has been shown to modulate many signaling
pathways leading to cell adhesion and migration, angiogenesis, myofibroblast activation, and extracellular matrix
deposition and remodeling, which together lead to tissue remodeling and fibrosis. It has been reported in the
literature that inhibition of CTGF expression by siRNA prevents CCl4-induced liver fibrosis and can reverse fibrosis
when administered after significant collagen deposition is observed. A monoclonal antibody to CTGF that is
currently in clinical development (FG-3019) has demonstrated the ability to reverse vascular stiffening and improve
cardiac function in a rat model of diabetic complications. FG-3019 has also exhibited activity in a murine radiation-
induced pulmonary fibrosis model. When FG-3019 was administered to mice after a significant radiation-induced
increase in lung density could be observed by CT imaging, the density of the lungs was observed to decrease over
the period during which the antibody was administered and to remain stable after therapy had ceased. When
considered together, these data indicate that inhibition of CTGF can prevent and reverse the process of fibrosis.
Introduction
CTGF and its modulation of cell biology
Connective tissue growth factor (CTGF, CCN2) is a mem-
ber of a small family of proteins that are characterized by
their highly conserved disulfide bonding pattern and hav-
ing 3-4 domains with homology to other proteins [1,2].
CTGF has four domains: domain 1 is homologous to IGF-
1 binding proteins, domain 2 is homologous to the von
Willebrand factor type C repeat, domain 3 is homologous
to the thrombospondin type 1 repeat and domain 4 con-
tains a cysteine knot motif that is common to proteins
that bind to heparan sulfate proteoglycans (HSPGs). The
two N-terminal domains (1 and 2) are linked to the two
C-terminal domains (3 and 4) by a peptide that is not
homologous to other proteins and is proteolytically labile.
The N-half of CTGF is proteolytically stable and can often
be observed in biological fluids (plasma, urine) of diseased
subjects, but is rarely observed at substantial levels in
healthy individuals [3,4]. The C-half of CTGF appears to
be proteolytically labile, and is rarely observed in biological
fluids. Similarly whole CTGF is rarely observed at signifi-
cant concentrations in biological fluids, except in subjects
with liver disease [5,6].
Although it was called CTGF when it was discovered [7],
it does not behave like a traditional growth factor or cyto-
kine since it does not appear to have a unique receptor to
which it binds with high affinity to induce signal transduc-
tion. It may be more accurate to think of CTGF as a
matricellular protein that modulates the interaction of
cells with the matrix to modify the cellular phenotype
[8-11]. Matricellular proteins such as SPARC, osteopontin
and thrombospondins represent a sub-class of extracellu-
lar matrix (ECM) proteins that do not provide a structural
function, but instead modulate cellular functions and sig-
naling through multiple mechanisms that depend on the
cell type and context [8].
CTGF has been reported to interact with a variety of
molecules after being secreted from cells (Figure 1).
Some of the molecules with which CTGF has been
reported to interact are cytokines and growth factors FibroGen, Inc., 409 Illinois St., San Francisco, CA 94158, USA
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molecules are cell surface receptors with other known
ligands such as TrkA, LRP1, LRP6 and several different
integrins. CTGF has also been reported to interact with
matrix proteins such as fibronectin or heparan sulfate
proteoglycans (HSPGs) that may be in the matrix or on
the cell surface. Interaction with each of these various
molecules has been reported to be dependent on the dif-
ferent domains of CTGF.
The interaction of CTGF with various molecules is
thought to positively or negatively alter the signal trans-
duction pathways in which they participate. The result
of this modulation of signaling are changes in cell adhe-
sion and migration, angiogenesis and vascular perme-
ability, differentiation, including myofibroblast formation
and activation, extracellular matrix deposition and
remodeling, all of which together lead to tissue remodel-
ing and changes in organ structure.
A l t h o u g ht h ed o g m ai nt h eC T G Fl i t e r a t u r es u g g e s t s
that all of the biological responses to CTGF are mediated
by the direct interaction of CTGF with cytokines or
receptors, the mechanisms by which it modulates cell
f u n c t i o na r el i k e l yt ob em o r ec o m p l i c a t e d .T h e r ea r ea t
least 5 mechanisms by which CTGF could simulta-
neously modulate the cellular environment and pheno-
type: 1) CTGF could act as an extracellular adapter
protein by binding to cytokines and helping to present
them to their receptors to stimulate response (e.g. TGFb
[12]) or sequestering them in the matrix and thereby pre-
venting them from stimulating signal transduction (e.g.
VEGF [13]); 2) CTGF could competitively bind to
HSPGs, which would displace heparin-binding growth
factors or receptor antagonists and thereby alter their
local concentration and ability to modulate signaling
(data not shown); 3) CTGF can block matrix binding
sites or create new matrix binding sites, which would
alter matrix signaling, cell adhesion and motility (e.g.
[14-16]); 4) CTGF can bind directly to cell surface recep-
tors and stimulate signal transduction (e.g. [16-18]); and
5) CTGF may be taken up into cells via endocytic path-
ways and act as an intracellular adapter protein to modu-
late signal transduction pathways in the cytoplasm and/
or nucleus [19]. Because CTGF can work through so
many mechanisms simultaneously, its biology is very
complicated and incompletely understood. In addition,
response to CTGF will be context dependent, and will
vary with matrix, cytokine environment and cell geno-
type. As a result, the literature is filled with apparent con-
tradictions of the effects of CTGF.
CTGF is a central mediator of tissue remodeling and
fibrosis
Regardless of the complexity of the mechanism of action
by which CTGF modulates cell biology, it is very clear
that CTGF plays a central role in diseases in which tissue
remodeling occurs (Figure 2). CTGF expression is
induced by many cytokines and conditions associated
with pathophysiology [20]. Its presence induces forma-
tion of myofibroblasts through transdifferentiation of
other cells, including epithelial cells (via EMT, epithelial
to mesenchymal transition) [21], stellate cells [22], resi-
dent fibroblasts [23] or fibrocytes (bone-marrow-derived,
Figure 1 CTGF affects multiple signaling pathways and processes important in pathophysiology. CTGF interacts with a variety of
molecules, including cytokines and growth factors, receptors and matrix proteins. These interactions alter signal transduction pathways, either
positively or negatively, which results in changes in cellular responses.
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recruited to an organ through chemokines [24]. CTGF
also activates the myofibroblasts and stimulates their
deposition and remodeling of ECM (extracellular matrix)
proteins. This leads to tissue remodeling and fibrosis.
When the tissue remodeling occurs in the vasculature, it
can create local hypertension that can induce CTGF
expression [25-27], thereby setting up a positive feedback
loop leading to more tissue remodeling. CTGF also
induces the expression of a variety of cytokines such as
TGFb [28] and VEGF [29], which induce more expres-
sion of CTGF. Thus, there are multiple positive feedback
loops involving CTGF expression that can contribute to
the progressive nature of fibrosis. By inhibiting CTGF,
these positive feedback loops can be broken, which
should enable organs to restore their normal wound heal-
ing response and their normal structure and function.
CTGF has also been reported to inhibit BMP-7 signaling
in diabetic kidney disease [30]. Since BMP-7 is thought to
counteract the pro-fibrotic effects of TGFb [31,32], inhibi-
tion of CTGF might also restore an anti-fibrotic regulatory
pathway. Thus, inhibition of CTGF has the potential to
modulate both pro- and anti-fibrotic mechanisms in a
direction that could enable reversal of fibrotic processes.
FG-3019
In order to identify an inhibitor of CTGF with the poten-
tial to be developed into a therapeutic agent, FibroGen
screened a library of human anti-CTGF antibodies to
select those that bound to CTGF with reasonable affinity
and exhibited activity in both in vitro assays and in vivo
models of disease. FG-3019 was chosen as a clinical can-
didate that has now progressed to phase II testing. FG-
3019 binds to the second domain of CTGF of all species
tested. We have used FG-3019 in animal models of dis-
ease to test whether inhibition of CTGF could reverse
pathophysiologic tissue remodeling and fibrosis.
Discussion
CTGF is required for the fibrotic activity of TGFb
In 1999, Mori et al. reported that CTGF was required to
observe persistent fibrosis after injection of TGFb into
rodents [33]. We and others have been able to confirm
their observations in several different experimental mod-
els, including one that closely resembles the experiment
they performed (Figure 3). One day old neonatal mice
were injected subcutaneously in the scapular region daily
for 7 days with TGFb2o rT G F b2 plus CTGF. The mice
were then maintained for another 4 days until they were
sacrificed and examined for deposition of ECM and cellu-
lar infiltration. As pointed out by the arrows in Figure 3
(panel B), TGFb induced a modest fibrotic response while
that induced by the combination of TGFb plus CTGF was
obviously greater. Co-injection of FG-3019 with the TGFb
and CTGF suppressed all of the response to the presence
of CTGF, demonstrating that the antibody was capable of
completely inhibiting the biological activity of CTGF.
The mechanism by which CTGF enables persistent
fibrosis upon stimulation by TGFb has never been eluci-
dated, due at least in part to the very complex mechanism
of action (MOA) of CTGF. In order to address one aspect
of the possible MOA, the role of CTGF in fibroblast pro-
liferation was explored. Primary human cardiac fibro-
blasts (ScienCell Research Laboratories) were examined
for serum-dependent production of CTGF and shown to
produce measurable amounts (Figure 4). The amount of
CTGF produced in these cells could be decreased by
infecting them with lentiviruses expressing CTGF
shRNAs (Open Biosystems). Knock down of CTGF
expression in these primary human cardiac fibroblasts
suppressed their ability to grow in medium containing
serum and added supplements, and after 9 days in cul-
ture, the number of cells correlated to the amount of
CTGF produced (Figure 4, Panel B). Assessment of the
doubling time of these cells showed that cells with lower
CTGF expression levels proliferated more slowly than
cells with normal expression levels, and the doubling time
appeared to correlate to the amount of CTGF expressed
(Figure 4, Panel C). These data indicate that autocrine
CTGF expression is critical for the ability of these fibro-
blasts to proliferate in response to serum and growth
supplements.
To evaluate the importance of CTGF for TGFb-
induced proliferation of these fibroblasts, cells were
Figure 2 CTGF is a central mediator of tissue remodeling and
fibrosis. Many different stimuli can induce expression of CTGF,
which then promotes formation of myofibroblasts by modulating
differentiation of other cells, including epithelial cells (EMT, epithelial
to mesenchymal transition), resident fibroblasts or recruited
fibrocytes (bone-marrow-derived, circulating mesenchymal stem
cells). CTGF also promotes activation of the myofibroblasts and
stimulates extracellular matrix (ECM) deposition and tissue
remodeling. Remodeling in the vasculature can produce local
hypertension that induces the expression of more CTGF, resulting in
a positive feedback loop. Other positive feedback loops result from
cytokines whose expression may be stimulated by CTGF, that in
turn induce the expression of CTGF.
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Page 3 of 8infected with lentiviruses expressing CTGF shRNAs or a
scrambled negative control shRNA (Figure 5). In serum-
starved cells infected with the scrambled shRNA, TGFb
induced expression of more CTGF than in unstimulated
fibroblasts. The CTGF shRNA suppressed CTGF expres-
sion in cells in control medium or medium supplemented
with TGFb (Figure 5, Panel A). TGFb stimulation of
fibroblasts infected with thel e n t i v i r u se x p r e s s i n gt h e
scrambled shRNA strongly increased the number of cells
after 7 days in culture. In contrast, TGFb stimulation of
fibroblasts infected with the lentiviruses expressing the
CTGF shRNAs exhibited no response to TGFb,a n dt h e
number of cells after 7 days in culture was lower than the
number of cells in unstimulated fibroblasts containing
the scrambled shRNA (Figure 5, Panel B). These data
suggest that CTGF expression is essential for fibroblast
proliferation, and in the absence of CTGF, fibroblasts are
unresponsive to stimuli like TGFb that would normally
strongly enhance their proliferation.
Inhibition of CTGF can reverse fibrosis
Data from experiments in several organ systems suggest
that inhibition of CTGF can not only prevent, but can
also inhibit fibrosis. For example, in liver fibrosis models
CTGF is known to increase in response to toxins such as
CCl4 [34] or dimethyl nitrosamine [35] or upon bile duct
ligation [34]. Inhibition of CTGF expression in a rodent
model of CCl4-induced liver fibrosis with siRNA can pre-
vent development of fibrosis [36]. If the CTGF siRNA is
administered to mice after significant increases of a-
smooth muscle actin (aSMA, a marker of myofibroblasts)
abundance and collagen deposition can be detected in
their liver, the fibrosis appears to regress within two
weeks [37].
To examine the cardiovascular complications of dia-
betes, rats were made diabetic with a single dose of
streptozotocin. After 6 weeks of diabetes, the rats were
divided into groups and treated for 6 weeks with FG-
3019 (10 mg/kg tiw) or the angiotensin converting
Figure 3 CTGF is essential for persistent fibrosis. One day old neonatal mice were injected SC daily for 7 days with 800 ng TGFb2 alone or
with 400 ng CTGF. FG-3019 was also administered to one group that received CTGF. The injections were then stopped for 4 days and the mice
were sacrificed to examine the deposition of ECM components and cellular invasion. Panel A: the experimental design. Panel B: A cross section
of the skin, SC space and underlying muscle from representative mice is shown. The arrows point out fibrotic response to the various
treatments.
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Page 4 of 8enzyme inhibitor captopril (75 mg/kg qd). The function
of the hearts of the rats in the various groups was then
measured prior to their sacrifice and removal of their
carotid arteries for measurement of vascular stiffness.
After 6 weeks of diabetes, the stiffness of the carotid
arteries in the axial orientation was greater than that of
healthy control animals. The axial stiffness continued to
increase during the next 6 weeks of diabetes. In rats
that began receiving captopril after 6 weeks of diabetes,
further progression of vascular stiffening was halted, and
Figure 4 CTGF knock-down with shRNA inhibits serum-dependent cell proliferation of cardiac fibroblasts. Primary cardiac fibroblasts (P)
were infected with lentiviruses encoding 2 different CTGF shRNAs (h2 and h5 from OpenBiosystems) or with a lentivirus generated from an
empty vector (V) as control. Panel A: CTGF protein expression was measured by ELISA in culture supernatants. Panel B: 96 hrs after infection, cells
were re-plated in quadruplicate wells of a 96-well plate in medium containing serum and defined growth supplements and incubated for up to
10 days. Cell proliferation was measured by Cyquant Fluorescense Intensity at the indicated timepoints. Panel C: Parallel cultures of cells were
stained with crystal violet at day 10 and doubling time (DT) was determined by linear regression analysis on the data shown in B. * p < 0.001 vs.
vector by ANOVA.
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observed at 6 weeks. In contrast, in rats that received
FG-3019 for 6 weeks beginning 6 weeks after they
became diabetic, the axial stiffness of the carotid arteries
in these diabetic rats reverted to that of healthy control
animals. In addition the function of the heart could also
be shown to be normalized in animals that received FG-
3019, but not in those administered captopril [38].
These data indicate that cardiovascular remodeling
associated with the complications of diabetes can be
reversed upon treatment with FG-3019.
To evaluate the effect of FG-3019 in pulmonary fibro-
sis, a radiation-induced model was used and preliminary
data were reported at an American Thoracic Society
meeting [39-41]. Pulmonary fibrosis was initiated with a
single, full thorax irradiation (20 Gy) to mice and FG-
3019 was administered for 8 weeks beginning at various
times before or after irradiation. Lung density of all
Figure 5 CTGF knock-down with shRNA inhibits TGFb-dependent cell proliferation of cardiac fibroblasts. Primary cardiac fibroblasts (P)
were infected with lentiviruses encoding CTGF shRNAs (h2 or h5) or with a lentivirus expressing a scrambled shRNA as control. Cells were serum
starved for 24 hrs and replated in medium containing growth supplements and the indicated concentrations of TGFb (TGFb). Panel A: CTGF
protein expression was measured after 7 days. Panel B: Cell proliferation was measured by Cyquant at the indicated timepoints.
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(CT).
Irradiation induced lung remodeling beginning around
12 weeks, and FG-3019 attenuated this remodeling in a
schedule-dependent manner. Lung density in the group
administered FG-3019 beginning 16 weeks after irradia-
tion had already significantly increased at the time that
FG-3019 administration began, and decreased with
treatment, indicating reversal of the radiation-induced
changes [39].
Thus, inhibition of CTGF in liver, the cardiovascular
system or the lungs has the potential to reverse tissue
remodeling and the process of fibrosis. Together, the
results from these studies suggest that inhibition of
CTGF may benefit any disease in which tissue remodel-
ing is important. For example, pancreatic cancers are
known to be very desmoplastic [42] and to exhibit strong
CTGF expression [43,44]. Data suggest that CTGF can
have both direct and indirect effects on pancreatic can-
cers [45-48]. Therefore, the use of FG-3019 for treatment
of pancreatic cancer is being explored in parallel with
hepatitis B-induced liver fibrosis and idiopathic pulmon-
ary fibrosis.
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